CIZZLE BIOTECHNOLOGY HOLDINGS PLC Cizzle Biotechnology Holdings Plc Share Price
Equities
PSL
GB00BNG2VN02
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.675 GBX | -5.63% |
|
-1.47% | -14.10% |
| 04-30 | EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down | AN |
| 04-30 | Cizzle Biotechnology Holdings Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 7.09M 8.99M 709M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | -1M -1.27M -100M | EV / Sales 2022 | - |
| Net cash position 2022 | 478K 606K 47.8M | Net cash position 2023 | 1.56M 1.97M 156M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.63
x | P/E ratio 2023 |
-4.04
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.98% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -5.63% | ||
| 1 week | -1.47% | ||
| Current month | +1.52% | ||
| 1 month | -4.29% | ||
| 3 months | -23.86% | ||
| 6 months | -9.46% | ||
| Current year | -14.10% |
1 week
1.60
1.85
1 month
1.571.85
Current year
1.573.38
1 year
1.573.38
3 years
1.309.50
5 years
1.3013.00
10 years
1.3013.00
| Managers | Title | Age | Since |
|---|---|---|---|
Nigel Lee
DFI | Director of Finance/CFO | 63 | 13/05/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dawn Coverley
BRD | Director/Board Member | 59 | 13/05/21 |
Nigel Lee
DFI | Director of Finance/CFO | 63 | 13/05/21 |
John Treacy
BRD | Director/Board Member | 42 | 28/01/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/24 | 1.675 | -5.63% | 1,553,414 |
| 14/05/24 | 1.775 | 0.00% | 415,414 |
| 13/05/24 | 1.775 | +4.41% | 1,513,628 |
| 10/05/24 | 1.7 | 0.00% | 132,912 |
| 09/05/24 | 1.7 | 0.00% | 1,422,919 |
Delayed Quote London S.E., May 15, 2024 at 04:35 pm
More quotes
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.10% | 8.41M | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +50.47% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| -1.62% | 11.98B |
- Stock Market
- Equities
- PSL Stock
